全球心房颤动药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

全球心房颤动药物市场需求预计将从 2023 年的 221.3 亿美元达到 2032 年近 302.6 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 3.54%。

心房颤动，通常称为 AFib，是指心臟上腔快速且不规则的跳动所导致的异常心臟状况。心房颤动药物或药物用于透过调节心率以预防血栓来治疗和管理 AFib 病症。心房颤动会阻止血液从心房正常流向心室。 AFib 药物帮助心臟的上心室和下心室协同工作，更好地泵血。心房颤动药物的作用是预防血栓、重置心律、降低中风风险并控制心率。

市场动态

全球老年人口的增加、肥胖、慢性病和缺血性心臟病的高盛行率构成了 AFib 疾病的高风险因素。预计这些因素将推动心房颤动药物市场的发展。此外，全球酒精消费的稳定成长可能会推动市场成长。然而，抗凝血剂的高成本以及与服用心房颤动药物相关的不良反应可能会限制全球市场。 SARS-CoV-2病毒引起的疫情正在导致缺氧，这可能会导致感染患者特别是老年人出现心房颤动。预计这一因素将为 AFib 药物製造商创造利润丰厚的商业前景。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球心房颤动药物市场的各个细分市场进行了包容性评估。心房颤动药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

心房颤动药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按产品分类

• 抗心律不整药物
• 抗凝血药物（维生素 K 拮抗剂 (VKA)、新型口服抗凝血剂 (NOAC)（直接凝血酶抑制剂、直接 Xa 因子抑制剂））

按心房颤动类型

• 阵发性
• 执着的
• 永恆的

按申请

• 心律控制
• 心率控制

依给药途径

• 口服
• 可注射

按最终用途

• 医院
• 心臟中心
• 门诊手术中心
• 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲房颤药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。心房颤动药物市场的主要参与者包括强生、辉瑞、赛诺菲、拜耳公司、勃林格殷格翰、百时美施贵宝、第一三共、阿斯特捷利康。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：心房颤动药物 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按产品分類的市场吸引力分析
  • 心房颤动类型的市场吸引力分析
  • 市场吸引力分析：依应用分类
  • 按给药途径进行的市场吸引力分析
  • 按最终用途分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球心房颤动药物市场分析：依产品分类

• 概述（按产品）
• 按产品分类的历史和预测资料分析
• 抗心律不整药物
• 抗凝血药物（维生素 K 拮抗剂 (VKA)、新型口服抗凝血剂 (NOAC)（直接凝血酶抑制剂、直接 Xa 因子抑制剂））

第 6 章：全球心房颤动药物市场分析：按心房颤动类型

• 依心房颤动类型概述
• 按心房颤动类型进行历史和预测数据分析
• 阵发性
• 执着的
• 永恆的

第 7 章：全球心房颤动药物市场分析：依应用分类

• 概述：按应用
• 历史和预测数据分析：按应用
• 心律控制
• 心率控制

第 8 章：全球心房颤动药物市场分析：依给药途径

• 依给药途径概述
• 按给药途径进行历史和预测资料分析
• 口服
• 可注射

第 9 章：全球心房颤动药物市场分析：依最终用途分类

• 按最终用途分类的概述
• 按最终用途分类的历史和预测资料分析
• 医院
• 心臟中心
• 门诊手术中心
• 其他的

第 10 章：全球心房颤动药物市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区按国家销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲按国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 11 章：心房颤动药物公司的竞争格局

• 心房颤动药物市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 12 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Johnson & Johnson
• 公司概况
• 公司收入
• 产品
• 最新动态
• Pfizer
• 公司概况
• 公司收入
• 产品
• 最新动态
• Sanofi
• 公司概况
• 公司收入
• 产品
• 最新动态
• Bayer AG
• 公司概况
• 公司收入
• 产品
• 最新动态
• Boehringer Ingelheim
• 公司概况
• 公司收入
• 产品
• 最新动态
• Bristol-Myers Squibb
• 公司概况
• 公司收入
• 产品
• 最新动态
• Daiichi Sankyo
• 公司概况
• 公司收入
• 产品
• 最新动态
• AstraZeneca
• 公司概况
• 公司收入
• 产品
• 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

The global demand for Atrial Fibrillation Drugs Market is presumed to reach the market size of nearly USD 30.26 Billion by 2032 from USD 22.13 Billion in 2023 with a CAGR of 3.54% under the study period 2024-2032.

Atrial fibrillation, commonly known as AFib refers to an abnormal heart condition interpreted by the rapid and irregular beating of the upper chambers of the heart. Atrial fibrillation drugs or medicines are used for the treatment and management of AFib conditions by regulating heart rate to prevent blood clots. AFib condition prevents blood from flowing normally from atria to the ventricles. The AFib medicines help the heart's upper and lower chambers to work together to pump blood better. The atrial fibrillation drugs work by preventing blood clots, resets heart rhythm, lower the chances of a stroke, and control the heart rate.

MARKET DYNAMICS

The global rise in the elderly population, obesity, high prevalence of chronic diseases, and ischemic heart diseases pose high-risk factors for AFib condition. These factors are anticipated to fuel atrial fibrillation drug markets. Also, the steady growth of global alcohol consumption may drive market growth. However, the high cost of anticoagulants and adverse effects associated with the consumption of Afib drugs exhibit the potential to restrain the global market. The pandemic caused by the SARS-CoV-2 virus is causing hypoxia, which may bring about atrial fibrillation in the infected patients specifically elderly. This factor is foreseen to create lucrative business prospects for AFib drug manufacturers.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Atrial Fibrillation Drugs. The growth and trends of Atrial Fibrillation Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Atrial Fibrillation Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Antiarrhythmic Drugs
• Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors))

By Atrial Fibrillation Type

• Paroxysmal
• Persistent
• Permanent

By Application

• Heart Rhythm Control
• Heart Rate Control

By Route of Administration

• Oral
• Injectable

By End-use

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Atrial Fibrillation Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Atrial Fibrillation Drugs market include Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, AstraZeneca. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ATRIAL FIBRILLATION DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Atrial Fibrillation Type
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Route of Administration
  • 3.7.5 Market Attractiveness Analysis By End-use
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data Analysis By Product
• 5.3. Antiarrhythmic Drugs Historic and Forecast Sales By Regions
• 5.4. Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors)) Historic and Forecast Sales By Regions

6. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY ATRIAL FIBRILLATION TYPE

• 6.1. Overview By Atrial Fibrillation Type
• 6.2. Historical and Forecast Data Analysis By Atrial Fibrillation Type
• 6.3. Paroxysmal Historic and Forecast Sales By Regions
• 6.4. Persistent Historic and Forecast Sales By Regions
• 6.5. Permanent Historic and Forecast Sales By Regions

7. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. Heart Rhythm Control Historic and Forecast Sales By Regions
• 7.4. Heart Rate Control Historic and Forecast Sales By Regions

8. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 8.1. Overview By Route of Administration
• 8.2. Historical and Forecast Data Analysis By Route of Administration
• 8.3. Oral Historic and Forecast Sales By Regions
• 8.4. Injectable Historic and Forecast Sales By Regions

9. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY END-USE

• 9.1. Overview By End-use
• 9.2. Historical and Forecast Data Analysis By End-use
• 9.3. Hospitals Historic and Forecast Sales By Regions
• 9.4. Cardiac Centers Historic and Forecast Sales By Regions
• 9.5. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
• 9.6. Others Historic and Forecast Sales By Regions

10. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE ATRIAL FIBRILLATION DRUGS COMPANIES

• 11.1. Atrial Fibrillation Drugs Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF ATRIAL FIBRILLATION DRUGS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Johnson & Johnson
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Pfizer
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Sanofi
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. Bayer AG
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Boehringer Ingelheim
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Bristol-Myers Squibb
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Daiichi Sankyo
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. AstraZeneca
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Product (USD MN)
• Antiarrhythmic Drugs Market Sales By Geography (USD MN)
• Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors)) Market Sales By Geography (USD MN)
• Analysis By Atrial Fibrillation Type (USD MN)
• Paroxysmal Market Sales By Geography (USD MN)
• Persistent Market Sales By Geography (USD MN)
• Permanent Market Sales By Geography (USD MN)
• Analysis By Application (USD MN)
• Heart Rhythm Control Market Sales By Geography (USD MN)
• Heart Rate Control Market Sales By Geography (USD MN)
• Analysis By Route of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Injectable Market Sales By Geography (USD MN)
• Analysis By End-use (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Cardiac Centers Market Sales By Geography (USD MN)
• Ambulatory Surgical Centers Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Atrial Fibrillation Drugs Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Atrial Fibrillation Drugs Report
• Market Research Process
• Market Research Methodology
• Global Atrial Fibrillation Drugs Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Product
• Market Attractiveness Analysis By Atrial Fibrillation Type
• Market Attractiveness Analysis By Application
• Market Attractiveness Analysis By Route of Administration
• Market Attractiveness Analysis By End-use
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Product (USD MN)
• Antiarrhythmic Drugs Market Sales By Geography (USD MN)
• Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors)) Market Sales By Geography (USD MN)
• Global Market Analysis By Atrial Fibrillation Type (USD MN)
• Paroxysmal Market Sales By Geography (USD MN)
• Persistent Market Sales By Geography (USD MN)
• Permanent Market Sales By Geography (USD MN)
• Global Market Analysis By Application (USD MN)
• Heart Rhythm Control Market Sales By Geography (USD MN)
• Heart Rate Control Market Sales By Geography (USD MN)
• Global Market Analysis By Route of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Injectable Market Sales By Geography (USD MN)
• Global Market Analysis By End-use (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Cardiac Centers Market Sales By Geography (USD MN)
• Ambulatory Surgical Centers Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.